XBiotech
XBIT
48 hedge funds and large institutions have $59.3M invested in XBiotech in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 16 reducing their positions, and 5 closing their positions.
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
69% more capital invested
Capital invested by funds: $35.1M → $59.3M (+$24.2M)
0% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 16
0.46% less ownership
Funds ownership: 10.69% → 10.23% (-0.46%)
2% less funds holding
Funds holding: 49 → 48 (-1)
12% less call options, than puts
Call options by funds: $2.9M | Put options by funds: $3.29M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$16.9M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$851K |
| 3 |
CIA
Capital Impact Advisors
Boston,
Massachusetts
|
+$685K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$444K |
| 5 |
Goldman Sachs
New York
|
+$320K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$494K |
| 2 |
Morgan Stanley
New York
|
-$454K |
| 3 |
SO
STRS Ohio
Columbus,
Ohio
|
-$268K |
| 4 |
Citigroup
New York
|
-$258K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$185K |
XBIT Hedge Fund Activity: Q1 2017 in Review
48 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q1 2017, worth a combined $59.3M — up 69% from $35.1M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new XBIT positions and 5 closed out — a net gain of 4 holders — while 16 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock, adding an estimated $16.9M. The largest seller was Susquehanna International Group, cutting an estimated $494K.
- 48 institutional investors held XBiotech (XBIT) as of Q1 2017, down from 49 in Q4 2016.
- Funds reported $59.3M of XBiotech stock for Q1 2017, up 69% quarter-over-quarter.
- 9 funds opened new XBiotech positions in Q1 2017 and 5 closed out, a net change of +4 holders.
- The largest XBiotech buyer in Q1 2017 was BlackRock, an estimated $16.9M added.
- The largest XBiotech seller in Q1 2017 was Susquehanna International Group, an estimated $494K sold.
Based on aggregated 13F filings for Q1 2017.